Onyx Pharmaceuticals (ONXX -2.5%) slips after the FDA says the toxic side effects of...

|By:, SA News Editor

Onyx Pharmaceuticals (ONXX -2.5%) slips after the FDA says the toxic side effects of carfilzomib, an experimental cancer drug for multiple myeloma, may outweigh its benefits. Staff reviewers are worried about the risk of patient deaths and questioned whether the effectiveness of the drug is that great, saying in a report the drug "may not provide an advantage over available therapy."